AUM Bioscience

Competitive
Landscape
Evaluating players in Oncology Treatment Development
 Company Profile

AUM is a clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on

AUM Bioscience
discovering, acquiring, and developing novel therapeutics in oncology. The company holds
exclusive worldwide rights in all disease indications for 2 first-in-class technologies with strong
composition of matter patents in all major territories. AUM is headquartered in Singapore.

IDEAYA is an oncology-focused precision medicine company. Ideaya Biosciences is committed

to the discovery and development of targeted therapeutics for patient populations selected
Ideaya using molecular diagnostics. It is advancing therapeutics that have the potential to be
first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class
of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise

in epigenetics to discover and develop novel therapeutics that address serious unmet medical
needs in patients with cancers associated with abnormal gene expression. Its integrated
Constellation
epigenetics platform enables it to validate targets and generate small molecules against these
targets that selectively modulate gene expression in tumor and immune cells to drive
anti-tumor activity. Constellation Pharmaceaticals is based in Cambridge, MA.
 Key Competitive Advantage Target Market Marketing Strategy

AI-augmented platform to systematically discover and develop targeted Working predominantly in the
cancer therapies. Asian Cancer Patients. Unmet
Asia-Pacific region, thereby
AUM Bioscience medical needs in oncology focusing
addressing the needs of the region
Ideally poised to address growing industry needs for designing faster and on Asia-Pacific cancers
more affordable treatment strategies distinctly for the Asian landscape while delivering a global solution.

IDEAYA SL Platform integrates extensive proprietary and public data sets

with orthogonal and complementary content Bioinformatic analysis In process of building a marketing
Large addressable patient
enables identification and validation of synthetic lethal target / biomarker and sales management organization
Ideaya populations in major solid tumor
interactions across vast datasets Robust SL interactions validated to create and implement marketing
types
genetically (Dual CRISPR, paralogues, isogenic pairs, CRISPR/siRNA), strategies
pharmacologically, & in vivo

Pioneer in the discovery and development of novel therapeutics that Not yet established a full Plan to commercialize them in the
Constellation target the writer, reader and eraser classes of epigenetic regulators and commercial organization or United States with own focused
modulate gene expression in a highly selective manner. distribution capabilities specialty sales force
 Strength Weakness Opportunities Threats

Strong linkages to local research on Being based out of Singapore,

Asia-Pacific prevalent cancers and the AUM sits at the commercial
AUM Bioscience
process of successful commercialization of epicentre of the Western and
drugs Eastern hemispheres.

IDEAYA has established a fully-integrated
platform that enables synthetic lethality
target and biomarker discovery, drug
Ideaya
discovery, functional genomic and
pharmacological validation, translational
research and opportunity expansion.
An early-stage
biopharmaceutical company Competitors have significantly
with a limited operating history greater financial, technical and
and no products approved for human resources. Competition in
commercial sale. Never an environment of rapid
completed a clinical trial, and technological and scientific
may be unable to do so for any change
of our product candidates

Deep understanding of the biological

context in which epigenetic regulators
operate, the development of
Constellation small-molecule product candidates that
selectively modulate their activity and the
design of clinical development programs
supported by novel biomarker strategies.